In this sense, it has been suggested that the EGFR inhibitor Gefitinib was able to decrease PD-L1 expression and inhibition of T-cell-mediated lysis of liver cancer cells through EGFR activation [45]. The gene discussed is CD274; the disease is liver cancer.